HUTCHMED(00013),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00013 HUTCHMED

Market Closed 01-03 16:08:08

23.250

-0.150

-0.64%

High24.200	Low22.850	Vol8.27M
Open23.550	D1 Closing23.400	Amplitude5.77%
Mkt Cap20.27B	Tradable Cap20.27B	Total Shares872.00M
T/O193.33M	T/O Rate0.95%	Tradable Shares872.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"HUTCHMED","latestPrice":23.25,"timestamp":1735891688023,"preClose":23.4,"halted":0,"volume":8269500,"delay":0,"floatShares":872000000,"shares":872000000,"eps":0.9226269650510659,"marketStatus":"Market Closed","change":-0.15,"latestTime":"01-03 16:08:08","open":23.55,"high":24.2,"low":22.85,"amount":193325523,"amplitude":0.057692,"askPrice":23.25,"askSize":8000,"bidPrice":23.2,"bidSize":21000,"shortable":3,"etf":0,"ttmEps":-0.3821824998638757,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1736127000000},"marketStatusCode":7,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":23.4,"openAndCloseTimeList":[[1735867800000,1735876800000],[1735880400000,1735891200000]],"volumeRatio":0.8489143965127447,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2500427944","title":"Hutchmed Says China's Medicines Regulator Accepts NDA With Priority Review for Orpathys, Tagrisso Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2500427944","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500427944?lang=en_us&edition=fundamental","pubTime":"2025-01-02 19:20","pubTimestamp":1735816853,"startTime":"0","endTime":"0","summary":"Hutchmed   said late Wednesday that the China National Medical Products Administration has accepted and granted priority review to its New Drug Application for the combination of Orpathys and Tagrisso for the treatment of patients with a specific type of non-small cell lung cancer.The company said this acceptance also triggers a milestone payment from AstraZeneca , which is leading the development of Orpathys outside China.The decision was supported by data from a late-stage trial that evaluated the efficacy and safety of a combination of the two drugs in comparison to chemotherapy and met its primary endpoint of progression-free survival in an interim analysis.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4531","LU0320765992.SGD","BK4007","LU0889565916.HKD","AZN","BK1587","LU0109394709.USD","LU2417539215.USD","BK4588","LU2236285917.USD","BK1588","HCM","00013","LU2462157665.USD","BK4585","LU1829250122.USD","LU2456880835.USD","BK1191","MDCO","BK4568"],"gpt_icon":0},{"id":"2500594911","title":"Deals of the day-Mergers and acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2500594911","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500594911?lang=en_us&edition=fundamental","pubTime":"2025-01-02 18:47","pubTimestamp":1735814834,"startTime":"0","endTime":"0","summary":"Deals of the day-Mergers and acquisitionsJan 2 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Thursday:** Swisscom SCMN.S said that it has completed i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nL4N3NY0D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","VOD.UK","LU0161305163.EUR","BK5074","BK4588","BK4516","BK4520","LU0757432116.USD","LU0957799991.USD","LU0640478417.SGD","LU0972486137.USD","X","BK1588","00013","BK1191","BK1587","BK4585"],"gpt_icon":0},{"id":"2500912866","title":"HUTCHMED to Divest 45% Equity Stake in Shanghai Hutchison Pharmaceuticals for $608 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2500912866","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500912866?lang=en_us&edition=fundamental","pubTime":"2025-01-02 16:48","pubTimestamp":1735807688,"startTime":"0","endTime":"0","summary":"HUTCHMED (HCM) said Wednesday it has agreed to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals to GP Health Service Capital and Shanghai Pharmaceuticals in two transactions totaling a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","EQR","BK4531","BK4585","BK4007","BK1191","BK1587","BK1588","00013","BK4215","HCM"],"gpt_icon":0},{"id":"2500991824","title":"HUTCHMED (China) Combination Cancer Treatment Gets NDA; Share Prices Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500991824","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500991824?lang=en_us&edition=fundamental","pubTime":"2025-01-02 15:16","pubTimestamp":1735802203,"startTime":"0","endTime":"0","summary":"HUTCHMED   received approval for a New Drug Application   for a combination of drugs for treating non-small cell lung cancer , according to a Wednesday filing with the Hong Kong bourse.The combination of Orpathys and Tagrisso is used to treat patients with advanced or metastatic NSCLC that has EGFR mutations and MET amplification, especially after cancer progresses following initial EGFR inhibitor treatment.The pharmaceutical shares were up by 5% in recent trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1587","BK1191","00013","BK1588"],"gpt_icon":0},{"id":"2500918882","title":"HUTCHMED China Ltd  - US$608M Divestment of Non-Core Joint Venture","url":"https://stock-news.laohu8.com/highlight/detail?id=2500918882","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500918882?lang=en_us&edition=fundamental","pubTime":"2025-01-02 15:00","pubTimestamp":1735801207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUCCDKLJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1588","00013","BK1587"],"gpt_icon":0},{"id":"2500918880","title":"HUTCHMED (China) Ltd - Expects to Record Gain on Disposal of About $477 Mln Before Taxation","url":"https://stock-news.laohu8.com/highlight/detail?id=2500918880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500918880?lang=en_us&edition=fundamental","pubTime":"2025-01-02 15:00","pubTimestamp":1735801207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUCCDKLJ1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1588","00013","BK1191"],"gpt_icon":0},{"id":"2500076990","title":"HUTCHMED (China) Ltd - to Invest Proceeds in Developing Internal Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2500076990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500076990?lang=en_us&edition=fundamental","pubTime":"2025-01-02 15:00","pubTimestamp":1735801207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUCCDKLJ1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1588","BK1587","BK1191","00013"],"gpt_icon":0},{"id":"2500634967","title":"BUZZ-HK-listed Hutchmed jumps on health unit stake sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2500634967","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500634967?lang=en_us&edition=fundamental","pubTime":"2025-01-02 10:59","pubTimestamp":1735786754,"startTime":"0","endTime":"0","summary":"** Shares of pharmaceuticals manufacturer Hutchmed   jump as much as 11.8% to HK$25.2, their highest since Dec. 13   ** Hutchmed , controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and pivot towards core operations at the drugmaker   ** Hutchmed anticipates to report a profit of $477 million before income tax from the transaction   ** Hutchmed's largest shareholder is Hong Kong-listed conglomerate CK Hutchison    in which the billionaire investor has a 28.1% stake   ** Shares of CK Hutchison ease 1.6%   ** Hang Seng Commerce & Industry Index    slips 0.9%,  healthcare index    falls 1.4% and Hang Seng Index    declines 1.5% ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00001","00013"],"gpt_icon":0},{"id":"2500991961","title":"Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2500991961","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500991961?lang=en_us&edition=fundamental","pubTime":"2025-01-02 10:08","pubTimestamp":1735783723,"startTime":"0","endTime":"0","summary":"Hutchmed   expects to book a pre-tax gain of approximately $477 million after its wholly-owned subsidiary sold shares in Shanghai Hutchison Pharmaceuticals .The disposal involved selling a 35% stake to GP Health Service Capital for approximately $473 million and a 10% stake to Shanghai Pharma  for around $135 million.Before this transaction, SHPL, a joint venture operating its own-brand prescription drug business, was equally owned by Hutchmed's subsidiary and Shanghai TCM.With the completion of this sale, Hutchmed will maintain a 5% indirect interest in SHPL.Disposal proceeds will be used to bolster Hutchmed's core business operations and advance its antibody drug conjugate platform, according to a filing on Wednesday.Hutchmed's shares gained over 3% in early trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1197","02607","BK0097","BK0028","BK0020","00013","BK0187","BK7095","BK1588","BK1191","BK1587","BK0012","BK0099","BK0175","BK0196","SHP.AU","601607","BK0184","BK0188","BK0183","SES.SI","BK0209"],"gpt_icon":1},{"id":"1154742837","title":"Stock Track | HUTCHMED Soars 5.99% on Positive Regulatory News for Lung Cancer Drug Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=1154742837","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154742837?lang=en_us&edition=fundamental","pubTime":"2025-01-02 09:32","pubTimestamp":1735781560,"startTime":"0","endTime":"0","summary":"HUTCHMED's stock surged 5.99% in the pre-market session on Thursday, following the announcement that the company's New Drug Application  for the combination of ORPATHYS and TAGRISSO in lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy has been accepted and granted priority review status by the China National Medical Products Administration .The NDA submission was supported by data from the SACHI Phase III trial, which evaluated the efficacy and sa","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | HUTCHMED Soars 5.99% on Positive Regulatory News for Lung Cancer Drug Combo","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["00013"],"gpt_icon":0},{"id":"2500957146","title":"BRIEF-Hutchmed Says NDA Acceptance In China With Priority Review Status For Orpathys And Tagrisso Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2500957146","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500957146?lang=en_us&edition=fundamental","pubTime":"2025-01-02 08:01","pubTimestamp":1735776096,"startTime":"0","endTime":"0","summary":"Jan 1  - HUTCHMED  Ltd   :   * HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY REVIEW STATUS FOR ORPATHYS AND TAGRISSO COMBINATION IN LUNG CANCER PATIENTS WITH MET AMPLIFICATION AFTER PROGRESSION ON FIRST-LINE EGFR INHIBITOR THERAPY   * HUTCHMED  LTD - THIS ACCEPTANCE ALSO TRIGGERS A MILESTONE PAYMENT FROM ASTRAZENECASource text:    Further company coverage:    ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1191","BK1587","00013"],"gpt_icon":0},{"id":"2500957904","title":"HUTCHMED Announces Nda Acceptance in China With Priority Review Status for Orpathys® and Tagrisso® Combination in Lung Cancer Patients With Met Amplification After Progression on First-Line Egfr Inhibitor Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2500957904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500957904?lang=en_us&edition=fundamental","pubTime":"2025-01-02 08:00","pubTimestamp":1735776001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUA44CSW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1588","BK1587","BK1191","00013"],"gpt_icon":0},{"id":"2500957118","title":"HUTCHMED (China) Ltd - This Acceptance Also Triggers a Milestone Payment From AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2500957118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500957118?lang=en_us&edition=fundamental","pubTime":"2025-01-02 08:00","pubTimestamp":1735776001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUA44CSW6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","00013","BK1191","BK1588"],"gpt_icon":0},{"id":"2500230957","title":"HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2500230957","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500230957?lang=en_us&edition=fundamental","pubTime":"2025-01-02 08:00","pubTimestamp":1735776000,"startTime":"0","endTime":"0","summary":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan.  02, 2025  (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/02/3003295/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-ORPATHYS-and-TAGRISSO-Combination-in-Lung-Cancer-Patients-with-MET-amplification-After-Progression-on-Fir.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1496350502.SGD","BK4585","CNS","MET","BK4097","BK4135","OS","LU1989772840.SGD","BK1191","LU1989772923.USD","LU1989771016.USD","00013","BK4162","LU1291159041.SGD","BK4588","BK1587","BK1588"],"gpt_icon":0},{"id":"2500953548","title":"Billionaire Li Ka-shing’s Hutchmed in $608 mln health unit stake sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2500953548","media":"Reuters","labels":["shareholding","corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500953548?lang=en_us&edition=fundamental","pubTime":"2025-01-02 04:39","pubTimestamp":1735763941,"startTime":"0","endTime":"0","summary":"UPDATE 1-Billionaire Li Ka-shing’s Hutchmed in $608 mln health unit stake sales Updates with deal details in paragraphs 2,3 and 6, company background in paragraphs 4 and 5Jan 1 (Reuters) - Hutchmed (C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250101:nL1N3NX05Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00001","00013","601607"],"gpt_icon":0},{"id":"2500895816","title":"China-based Hutchmed to divest stake in health unit for $608 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2500895816","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500895816?lang=en_us&edition=fundamental","pubTime":"2025-01-02 04:09","pubTimestamp":1735762197,"startTime":"0","endTime":"0","summary":"Jan 2  - Hong Kong-headquartered biopharmaceutical company Hutchmed     on Wednesday said it will sell stakes in a health subsidiary to GP Health Service Capital and Shanghai Pharmaceuticals    for about $608 million.  ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1587","BK1191","00013"],"gpt_icon":0},{"id":"2500984831","title":"Li Ka-Shing-Backed Hutchmed Sells Stake in Unit for $608 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2500984831","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500984831?lang=en_us&edition=fundamental","pubTime":"2025-01-01 19:30","pubTimestamp":1735731032,"startTime":"0","endTime":"0","summary":"Biopharmaceutical firm Hutchmed China Ltd., backed by billionaire Li Ka-shing, has agreed to sell stakes in a health unit for about $608 million as the group seeks to generate capital and focus on its core businesses.","market":"fut","thumbnail":"https://www.bnnbloomberg.ca/resizer/v2/7SACPF4GGHPRD4EUL4MBDRPTWY.jpg?smart=true&auth=6078596d95c5f34a2633ed9c03828cd4736847abf0ae851a68bf39a66b59de9b&width=500&height=333","type":0,"news_type":0,"thumbnails":["https://www.bnnbloomberg.ca/resizer/v2/7SACPF4GGHPRD4EUL4MBDRPTWY.jpg?smart=true&auth=6078596d95c5f34a2633ed9c03828cd4736847abf0ae851a68bf39a66b59de9b&width=500&height=333"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/business/company-news/2025/01/01/li-ka-shing-backed-hutchmed-sells-stake-in-unit-for-608-million/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["BK1587","00013","BK1191","BK1588"],"gpt_icon":0},{"id":"2500309983","title":"BRIEF-HUTCHMED Announces $608 Mln Divestment Of Non-Core Joint Venture","url":"https://stock-news.laohu8.com/highlight/detail?id=2500309983","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500309983?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:53","pubTimestamp":1735728784,"startTime":"0","endTime":"0","summary":"Jan 1  - HUTCHMED  Ltd   :   * HUTCHMED ANNOUNCES US$608 MILLION DIVESTMENT OF NON-CORE JOINT VENTURE   * HUTCHMED  LTD - DIVESTMENT PROCEEDS TO ADVANCE HUTCHMED'S PIPELINE AND CORE INNOVATIVE MEDICINES BUSINESS   * HUTCHMED  LTD - HUTCHMED EXPECTS TO RECORD A GAIN ON DISPOSAL OF APPROXIMATELY US$477 MILLION BEFORE TAXATIONSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","00013","BK1191","BK4185","BK1587","JYNT"],"gpt_icon":0},{"id":"2500983904","title":"HUTCHMED- Entered Two Agreements to Divest 45% Equity Interest in Shanghai Hutchison Pharmaceuticals to Gp Health Service Capital, Shanghai Pharmaceuticals Holding","url":"https://stock-news.laohu8.com/highlight/detail?id=2500983904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500983904?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:46","pubTimestamp":1735728405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250101:nTUA2RBG6H:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0097","BK0196","BK0020","BK0188","601607","BK1191","00013","BK1587","BK0175","BK0209","BK0099","BK0183","BK0184","BK0012","BK0028","BK0187","BK1588"],"gpt_icon":0},{"id":"2500983834","title":"HUTCHMED (China) Ltd - Divestment Proceeds to Advance HUTCHMED's Pipeline and Core Innovative Medicines Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2500983834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500983834?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:46","pubTimestamp":1735728405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250101:nTUA2RBG6H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0097","BK0012","BK0184","BK0196","BK0183","BK0209","BK1191","BK0175","BK1587","BK0187","BK0188","BK0028","00013","BK0099","BK1588","601607","BK0020"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0426},{"period":"1month","weight":-0.1341},{"period":"3month","weight":-0.307},{"period":"6month","weight":-0.1941},{"period":"1year","weight":-0.153},{"period":"ytd","weight":0.031}],"compareEarnings":[{"period":"1week","weight":-0.0164},{"period":"1month","weight":0.0009},{"period":"3month","weight":-0.1309},{"period":"6month","weight":0.1102},{"period":"1year","weight":0.1871},{"period":"ytd","weight":-0.0149}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.090394},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058734},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.131658},{"month":4,"riseRate":0.666667,"avgChangeRate":0.04977},{"month":5,"riseRate":0,"avgChangeRate":-0.194502},{"month":6,"riseRate":0.333333,"avgChangeRate":0.018958},{"month":7,"riseRate":1,"avgChangeRate":0.135989},{"month":8,"riseRate":0.25,"avgChangeRate":-0.055482},{"month":9,"riseRate":0.5,"avgChangeRate":-0.020796},{"month":10,"riseRate":0.25,"avgChangeRate":-0.032252},{"month":11,"riseRate":0.5,"avgChangeRate":0.182346},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016836}],"exchange":"SEHK","name":"HUTCHMED","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HUTCHMED(00013),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HUTCHMED(00013) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HUTCHMED,00013,HUTCHMED股票,HUTCHMED股票老虎,HUTCHMED股票老虎国际,HUTCHMED行情,HUTCHMED股票行情,HUTCHMED股价,HUTCHMED股市,HUTCHMED股票价格,HUTCHMED股票交易,HUTCHMED股票购买,HUTCHMED股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HUTCHMED(00013),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HUTCHMED(00013) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}